title: Opioid Analgesics and Nicotine: More Than Blowing Smoke.
abstract: Practitioners are highly likely to encounter patients with concurrent use of nicotine products and opioid analgesics. Smokers present with more severe and extended chronic pain outcomes and have a higher frequency of prescription opioid use. Current tobacco smoking is a strong predictor of risk for nonmedical use of prescription opioids. Opioid and nicotinic-cholinergic neurotransmitter systems interact in important ways to modulate opioid and nicotine effects: dopamine release induced by nicotine is dependent on facilitation by the opioid system, and the nicotinic-acetylcholine system modulates self-administration of several classes of abused drugs-including opioids. Nicotine can serve as a prime for the use of other drugs, which in the case of the opioid system may be bidirectional. Opioids and compounds in tobacco, including nicotine, are metabolized by the cytochrome P450 enzyme system, but the metabolism of opioids and tobacco products can be complicated. Accordingly, drug interactions are possible but not always clear. Because of these issues, asking about nicotine use in patients taking opioids for pain is recommended. When assessing patient tobacco use, practitioners should also obtain information on products other than cigarettes, such as cigars, pipes, smokeless tobacco, and electronic nicotine delivery systems (ENDS, or e-cigarettes). There are multiple forms of behavioral therapy and pharmacotherapy available to assist patients with smoking cessation, and opioid agonist maintenance and pain clinics represent underutilized opportunities for nicotine intervention programs.
authors.forename: Jin H
authors.initials: JH
authors.lastname: Yoon
authors.forename: Scott D
authors.initials: SD
authors.lastname: Lane
authors.forename: Michael F
authors.initials: MF
authors.lastname: Weaver
mesh_terms: D000701:Analgesics, Opioid / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D059350:Chronic Pain / Q000188:drug therapy* / Q000453:epidemiology; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism; D004347:Drug Interactions; D006801:Humans; D018377:Neurotransmitter Agents / Q000378:metabolism*; D009538:Nicotine / Q000493:pharmacokinetics*; D011950:Receptors, Cholinergic / Q000378:metabolism; D011978:Receptors, Nicotinic / Q000378:metabolism; D011957:Receptors, Opioid / Q000378:metabolism; D018570:Risk Assessment; D012720:Severity of Illness Index; D012907:Smoking / Q000453:epidemiology / Q000503:physiopathology*; D062789:Tobacco Products
chemical_list: D000701:Analgesics, Opioid; D018377:Neurotransmitter Agents; D011950:Receptors, Cholinergic; D011978:Receptors, Nicotinic; D011957:Receptors, Opioid; D009538:Nicotine; D003577:Cytochrome P-450 Enzyme System; D004298:Dopamine
keywords: chronic pain; drug interactions; nicotine; opioids